This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), Nurix Therapeutics (NRIX) and Gilead Sciences (GILD)

Tipranks - Tipranks - Wed Jun 10, 5:32AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Edwards Lifesciences (EW), Nurix Therapeutics (NRIX) and Gilead Sciences (GILD) with bullish sentiments.

Introducing TipRanks MCP for Agents

Edwards Lifesciences (EW)

Bank of America Securities analyst Travis Steed maintained a Buy rating on Edwards Lifesciences today and set a price target of $100.00. The company’s shares closed last Monday at $85.85.

According to TipRanks.com, Steed is a 3-star analyst with an average return of 0.8% and a 49.6% success rate. Steed covers the Healthcare sector, focusing on stocks such as Kestra Medical Technologies Ltd., Bausch + Lomb Corporation, and Inspire Medical Systems. ;'>

Edwards Lifesciences has an analyst consensus of Strong Buy, with a price target consensus of $98.27, which is a 14.3% upside from current levels. In a report issued on May 27, Jefferies also maintained a Buy rating on the stock with a $102.00 price target.

See the top stocks recommended by analysts >>

Nurix Therapeutics (NRIX)

BTIG analyst Jeet Mukherjee maintained a Buy rating on Nurix Therapeutics yesterday and set a price target of $32.00. The company’s shares closed last Monday at $15.64.

According to TipRanks.com, Mukherjee is a 3-star analyst with an average return of 3.2% and a 43.8% success rate. Mukherjee covers the Healthcare sector, focusing on stocks such as Ascentage Pharma Group International Unsponsored ADR, Aardvark Therapeutics, Inc., and ArriVent BioPharma, Inc. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Nurix Therapeutics with a $32.70 average price target, representing a 95.5% upside. In a report released yesterday, Jefferies also maintained a Buy rating on the stock with a $45.00 price target.

Gilead Sciences (GILD)

Wells Fargo analyst Mohit Bansal maintained a Buy rating on Gilead Sciences yesterday and set a price target of $165.00. The company’s shares closed last Monday at $128.10.

According to TipRanks.com, Bansal is a 5-star analyst with an average return of 9.4% and a 57.0% success rate. Bansal covers the Healthcare sector, focusing on stocks such as Mineralys Therapeutics, Inc., BioMarin Pharmaceutical, and Vertex Pharmaceuticals. ;'>

Currently, the analyst consensus on Gilead Sciences is a Strong Buy with an average price target of $160.11, a 23.1% upside from current levels. In a report issued on May 26, Scotiabank also maintained a Buy rating on the stock with a $177.00 price target.

Read More on EW:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).